Back to All Events

Dedication to the 3Rs: Working Group Deliverables Generated by the IQ Consortium

IQ Webinar Series
Dedication to the 3Rs:
Working Group Deliverables Generated by the IQ Consortium

August – September 2024

 

29 August | 11 AM – 12 PM ET

Cross-Industry Husbandry Survey Findings and Its Impact on NHP Health Issue

Speakers:  Monika Burns, Novartis and Smita Salian-Mehta, Gilead
Moderator:  Kathy Orsted, Gilead

The incidence of NHPs with abnormal fecal changes and stress-related health conditions is a growing concern due to the severe shortage of NHPs and the use of younger animals. A deeper understanding of the extent and management of these issues is warranted as impact of animal health has a potential to interfere with data quality or interpretation. A cross-industry survey was conducted by the NHP Husbandry Working Group jointly cosponsored by the IQ Consortium's DruSafe and 3Rs Translational and Predictive Sciences Leadership Groups to determine the frequency of NHP health issues and benchmark current NHP husbandry practices to address these issues prior to placing animals on studies. Key findings from this initial survey indicated that excluding NHPs from study for gastrointestinal health issues and signs of abnormal stress resulted in a higher quality of study cohorts with better overall health. In addition, preventative health practices, especially diet modifications, environmental enrichment, and behavior assessment training have a positive impact on NHP health and study outcomes. This talk will also provide outcomes from a second survey that will be conducted for highlighting NHP health issues and husbandry practices utilized during the in-life study phase. This presentation will discuss the results from the pre-study phase survey and proposed recommendations for husbandry practices during the study phase that can minimize health issues, enhance animal welfare consistent with the 3Rs principle, and improve data quality from toxicity studies utilizing NHPs.

 

19 September | 11 AM – 12 PM ET

Recovery Animals Are Not Always Required

Speakers:  James Smith, Boehringer Ingelheim
Moderators:  Smita Salian-Mehta, Gilead and Kathy Orsted, Gilead

The inclusion of recovery animals in preclinical studies supporting clinical trials is undertaken with a diversity of approaches despite operating under the same 3Rs principles and guidances. While the use of recovery animals may provide valuable assessment of delayed toxicity or reversibility of adverse toxicity, there are instances where such an assessment may be confidently made while also minimizing animal use. This presentation uses specific case studies provided by IQ Consortium Recovery Animals Working Group members (sponsored by the IQ 3R TPS LG) to represent their company strategies and to highlight challenges and opportunities for continuous refinement in the use of recovery animals. Rationales behind the inclusion/exclusion of recovery animals will be shared with the goal of increasing awareness of successfully progressing drugs to clinical application while also minimizing the utilization of recovery animals.

 

3 October | 1 PM – 2 PM ET

In vitro 101: Introduction to Microphysiological Systems

Speakers:  Aaron Fullerton, Genentech, and Anna Kopec, Pfizer
Moderators:  David Kukla, AbbVie, Brianna Gaskill, Novartis, and Rosemary Santos, Pfizer

(Description forthcoming)

 

This webinar series is open to the public. Membership in the IQ Consortium is not required.